{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:09Z","timestamp":1793672829591,"version":"4.5.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09400-x","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:18:03Z","timestamp":1789190283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal disease control and pregnancy outcomes with anti-CD20 therapy versus natalizumab in multiple sclerosis: a systematic review"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1715-0749","authenticated-orcid":false,"given":"Abdulaziz","family":"Altamimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashayr Arif","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Essam","family":"Shaybah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen Essam","family":"Almahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Al","family":"Mazyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Sami","family":"Afash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf Abdulrahman Obaid","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nura Waleed","family":"Ghibban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwaym Jaber Mohammed","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Yousef","family":"Almohaimeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Hussain","family":"Ghazwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif Eid","family":"Alrashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Altamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"4","key":"9400_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3934\/Neuroscience.2025026","volume":"12","author":"ASPM Arachchige","year":"2025","unstructured":"Arachchige ASPM, El Choueiri J, Pellican\u00f2 F, Laurelli F, Alves GAM, Stomeo N (2025) A review of multiple sclerosis: From pathophysiology to latest therapeutic advances. AIMS Neurosci 12(4):514\u2013538. https:\/\/doi.org\/10.3934\/Neuroscience.2025026","journal-title":"AIMS Neurosci"},{"issue":"2","key":"9400_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/13625187.2024.2434843","volume":"30","author":"GS Merki-Feld","year":"2025","unstructured":"Merki-Feld GS et al (2025) Family planning and contraception in people with multiple sclerosis: perspectives for obstetricians, gynaecologists, and other health care professionals involved in reproductive planning. Eur J Contracept Reprod Health Care 30(2):59\u201373. https:\/\/doi.org\/10.1080\/13625187.2024.2434843","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"9400_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21556660.2020.1721507","volume":"9","author":"B Caniba\u00f1o","year":"2020","unstructured":"Caniba\u00f1o B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y (2020) Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess 9(1):20\u201336. https:\/\/doi.org\/10.1080\/21556660.2020.1721507","journal-title":"J Drug Assess"},{"issue":"1","key":"9400_CR4","doi-asserted-by":"publisher","first-page":"103061","DOI":"10.1016\/j.jogoh.2025.103061","volume":"55","author":"V Trabaud","year":"2026","unstructured":"Trabaud V, Zimmerman A, Gnisci A, Audoin B, Courbiere B (2026) Multiple sclerosis, fertility, pregnancy, and assisted reproductive technology: Current knowledge. J Gynecol Obstet Hum Reprod 55(1):103061. https:\/\/doi.org\/10.1016\/j.jogoh.2025.103061","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"6","key":"9400_CR5","doi-asserted-by":"publisher","first-page":"e200328","DOI":"10.1212\/NXI.0000000000200328","volume":"11","author":"WZ Yeh","year":"2024","unstructured":"Yeh WZ et al (2024) Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm 11(6):e200328. https:\/\/doi.org\/10.1212\/NXI.0000000000200328","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9400_CR6","doi-asserted-by":"publisher","unstructured":"Sahloul O, Louapre C, Beigneux Y, Lubetzki C, Maillart E, Roux T (2024) Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies. Mult Scler Relat Disord 85:105557. https:\/\/doi.org\/10.1016\/j.msard.2024.105557","DOI":"10.1016\/j.msard.2024.105557"},{"issue":"9","key":"9400_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/jnnp-2022-330533","volume":"94","author":"C Schubert","year":"2023","unstructured":"Schubert C et al (2023) Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatr 94(9):718\u2013725. https:\/\/doi.org\/10.1136\/jnnp-2022-330533","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"9400_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247","author":"M Lin","year":"2019","unstructured":"Lin M, Shi S, Zhang J, Yang CM, Luo J (2019) Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD013247","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"9400_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20\u2009+\u2009B-Cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14(4):835\u2013841. https:\/\/doi.org\/10.1007\/s13311-017-0557-4","journal-title":"Neurotherapeutics"},{"key":"9400_CR10","doi-asserted-by":"publisher","unstructured":"K\u00fcmpfel T et al (2021) Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. Neurol Neuroimmunol Neuroinflamm 8(1). https:\/\/doi.org\/10.1212\/NXI.0000000000000913","DOI":"10.1212\/NXI.0000000000000913"},{"issue":"11","key":"9400_CR11","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/acn3.51893","volume":"10","author":"A Anderson","year":"2023","unstructured":"Anderson A et al (2023) Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Ann Clin Transl Neurol 10(11):2053\u20132064. https:\/\/doi.org\/10.1002\/acn3.51893","journal-title":"Ann Clin Transl Neurol"},{"key":"9400_CR12","unstructured":"www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf (accessed Mar. 09, 2026)"},{"key":"9400_CR13","doi-asserted-by":"publisher","unstructured":"Demortiere S et al (2023) Disease evolution in women with highly active MS who suspended natalizumab during pregnancy vs rituximab\/ocrelizumab before conception. Neurol Neuroimmunol Neuroinflamm 10(5). https:\/\/doi.org\/10.1212\/NXI.0000000000200161","DOI":"10.1212\/NXI.0000000000200161"},{"issue":"10","key":"9400_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaneurol.2025.2550","volume":"82","author":"A Gavoille","year":"2025","unstructured":"Gavoille A et al (2025) Therapeutic management during pregnancy and relapse risk in women with multiple sclerosis. JAMA Neurol 82(10):994\u20131003. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2550","journal-title":"JAMA Neurol"},{"key":"9400_CR15","doi-asserted-by":"publisher","unstructured":"Thiel S, Litvin N, Haben S, Gold R, Hellwig K (2024) Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. J Neurol Neurosurg Psychiatr 95(6):561\u2013570. https:\/\/doi.org\/10.1136\/jnnp-2023-332804","DOI":"10.1136\/jnnp-2023-332804"},{"key":"9400_CR16","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ p. n 71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"9400_CR17","doi-asserted-by":"crossref","unstructured":"Higgins JP et al (2019) Cochrane handbook for systematic reviews of interventions. Cochrane Handb Syst reviews interventions","DOI":"10.1002\/9781119536604"},{"key":"9400_CR18","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"9400_CR19","doi-asserted-by":"publisher","unstructured":"Sportiello L et al (2023) Disease-modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of real-world data from EudraVigilance database. Pharmaceuticals (Basel) 16(11). https:\/\/doi.org\/10.3390\/ph16111566","DOI":"10.3390\/ph16111566"},{"issue":"4","key":"9400_CR20","doi-asserted-by":"publisher","first-page":"e200499","DOI":"10.1212\/CPJ.0000000000200499","volume":"15","author":"M Einsiedler","year":"2025","unstructured":"Einsiedler M et al (2025) Treatment strategies and disease activity during pregnancy and postpartum: real-world data from the Swiss multiple sclerosis cohort. Neurol Clin Pract 15(4):e200499. https:\/\/doi.org\/10.1212\/CPJ.0000000000200499","journal-title":"Neurol Clin Pract"},{"key":"9400_CR21","doi-asserted-by":"publisher","unstructured":"Bast N et al (2025) Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. Lancet Reg Health Eur 48:101137. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101137","DOI":"10.1016\/j.lanepe.2024.101137"},{"key":"9400_CR22","doi-asserted-by":"publisher","unstructured":"Hellwig K, Verdun di E, Cantogno, Sabid\u00f3 M (2021) A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 14:17562864211051012. https:\/\/doi.org\/10.1177\/17562864211051012","DOI":"10.1177\/17562864211051012"},{"issue":"4","key":"9400_CR23","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K (2024) Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol 271(4):1515\u20131535. https:\/\/doi.org\/10.1007\/s00415-023-12007-3","journal-title":"J Neurol"},{"key":"9400_CR24","doi-asserted-by":"publisher","unstructured":"de S\u00e8ze J et al (2023) Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol 14:1004795. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795","DOI":"10.3389\/fimmu.2023.1004795"},{"issue":"2","key":"9400_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/acn3.51965","volume":"11","author":"J Feige","year":"2024","unstructured":"Feige J et al (2024) Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets. Ann Clin Transl Neurol 11(2):450\u2013465. https:\/\/doi.org\/10.1002\/acn3.51965","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"9400_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/pn-2022-003426","volume":"23","author":"R Dobson","year":"2023","unstructured":"Dobson R et al (2023) Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Pract Neurol 23(1):6\u201314. https:\/\/doi.org\/10.1136\/pn-2022-003426","journal-title":"Pract Neurol"},{"issue":"4","key":"9400_CR27","doi-asserted-by":"publisher","first-page":"e200264","DOI":"10.1212\/NXI.0000000000200264","volume":"11","author":"C Schwake","year":"2024","unstructured":"Schwake C et al (2024) Neonatal B-cell levels and infant health in newborns potentially exposed to anti-CD20 monoclonal antibodies during pregnancy or lactation. Neurol Neuroimmunol Neuroinflamm 11(4):e200264. https:\/\/doi.org\/10.1212\/NXI.0000000000200264","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9400_CR28","doi-asserted-by":"publisher","unstructured":"Nguyen Ky M et al (2023) Natalizumab treatment induces proinflammatory CD4 T cells preferentially in the integrin \u03b27\u2009+\u2009compartment. Neurol Neuroimmunol Neuroinflamm 10(6). https:\/\/doi.org\/10.1212\/NXI.0000000000200166","DOI":"10.1212\/NXI.0000000000200166"},{"key":"9400_CR29","doi-asserted-by":"publisher","unstructured":"Klotz L et al (2025) Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook. Ther Adv Neurol Disord 18:17562864251372752. https:\/\/doi.org\/10.1177\/17562864251372752","DOI":"10.1177\/17562864251372752"},{"issue":"17","key":"9400_CR30","doi-asserted-by":"publisher","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","volume":"99","author":"I Roos","year":"2022","unstructured":"Roos I et al (2022) Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. Neurology 99(17):e1926\u2013e1944. https:\/\/doi.org\/10.1212\/WNL.0000000000201029","journal-title":"Neurology"},{"key":"9400_CR31","doi-asserted-by":"publisher","unstructured":"Jouvenot G et al (2024) High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol 81(5):490\u2013498. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0395","DOI":"10.1001\/jamaneurol.2024.0395"},{"issue":"10","key":"9400_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1791202","volume":"82","author":"EMV de Melo","year":"2024","unstructured":"de Melo EMV, Rodrigues BCA, Cabral FT, Villarim LAMT (2024) Mendes. Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era. Arq Neuropsiquiatr 82(10):1\u201311. https:\/\/doi.org\/10.1055\/s-0044-1791202","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"9400_CR33","doi-asserted-by":"publisher","first-page":"e200253","DOI":"10.1212\/CPJ.0000000000200253","volume":"14","author":"EL Graham","year":"2024","unstructured":"Graham EL et al (2024) Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths. Neurol Clin Pract 14(2):e200253. https:\/\/doi.org\/10.1212\/CPJ.0000000000200253","journal-title":"Neurol Clin Pract"},{"key":"9400_CR34","doi-asserted-by":"publisher","unstructured":"Anderson A et al (2021) Clinical and radiologic disease activity in pregnancy and postpartum in MS. Neurol Neuroimmunol Neuroinflamm 8(2). https:\/\/doi.org\/10.1212\/NXI.0000000000000959","DOI":"10.1212\/NXI.0000000000000959"},{"issue":"9","key":"9400_CR35","doi-asserted-by":"publisher","first-page":"e2531581","DOI":"10.1001\/jamanetworkopen.2025.31581","volume":"8","author":"J Shipley","year":"2025","unstructured":"Shipley J et al (2025) Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability. JAMA Netw Open 8(9):e2531581. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.31581","journal-title":"JAMA Netw Open"},{"issue":"1","key":"9400_CR36","doi-asserted-by":"publisher","first-page":"e200349","DOI":"10.1212\/NXI.0000000000200349","volume":"12","author":"S Vukusic","year":"2025","unstructured":"Vukusic S et al (2025) Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab. Neurol Neuroimmunol Neuroinflamm 12(1):e200349. https:\/\/doi.org\/10.1212\/NXI.0000000000200349","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9400_CR37","doi-asserted-by":"publisher","unstructured":"Gitman V, Stavropoulos A, Saenz V, Pasquarelli N, Zecevic D, Devonshire V (2022) Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data. Mult Scler Relat Disord 62:103792. https:\/\/doi.org\/10.1016\/j.msard.2022.103792","DOI":"10.1016\/j.msard.2022.103792"},{"key":"9400_CR38","doi-asserted-by":"publisher","unstructured":"Sacta MA, Jacobs K, Sun D, Lee J (2025) Ocrelizumab-Induced B-Cell Depletion in a Newborn. Pediatrics 156(3). https:\/\/doi.org\/10.1542\/peds.2025-070891","DOI":"10.1542\/peds.2025-070891"},{"issue":"3","key":"9400_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ctn8030026","volume":"8","author":"M Graber","year":"2024","unstructured":"Graber M et al (2024) Recommendations for the treatment of multiple sclerosis in family planning, pregnancy and lactation in switzerland: immunotherapy. Clin Translational Neurosci 8(3):26. https:\/\/doi.org\/10.3390\/ctn8030026","journal-title":"Clin Translational Neurosci"},{"issue":"8","key":"9400_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","volume":"47","author":"CA Gravel","year":"2024","unstructured":"Gravel CA, Bai W, Douros A (2024) Comparators in pharmacovigilance: a quasi-quantification bias analysis. Drug Saf 47(8):809\u2013819. https:\/\/doi.org\/10.1007\/s40264-024-01433-5","journal-title":"Drug Saf"},{"issue":"2","key":"9400_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/jnnp-2023-331525","volume":"95","author":"S Haben","year":"2024","unstructured":"Haben S et al (2024) Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis. J Neurol Neurosurg Psychiatr 95(2):151\u2013157. https:\/\/doi.org\/10.1136\/jnnp-2023-331525","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"9400_CR42","doi-asserted-by":"publisher","unstructured":"Bove R et al (2024) Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. Mult Scler Relat Disord 88:105738. https:\/\/doi.org\/10.1016\/j.msard.2024.105738","DOI":"10.1016\/j.msard.2024.105738"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09400-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:02:20Z","timestamp":1793671340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9400"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09400-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"778"}}